Global Injectable Targeted Therapy Market – Industry Trends and Forecast to 2029

Injectable Targeted Therapy Market Analysis and Size

The global injectable targeted therapy market is expected to witness significant growth during the forecast period. The growing incidence of cancer worldwide works as a key factor enhancing the growth of the global injectable targeted therapy market. In injectable targeted therapy, the dosage frequency recommended for the patient is reduced to ensure drug uniformity and increase its effectiveness. It also decreases the global side effects of drug imposition into the body while fighting against the cancer cells. The hospitals and clinics segment are anticipated to dominate the market due to the rising occurrence of chronic diseases, patient compliance, and technological advancements. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global injectable targeted therapy market in the forecast period 2022-2029. The expected CAGR of global injectable targeted therapy market is tend to be around 12% in the mentioned forecast period. The market was valued at USD 610.67 billion in 2021, and it would grow upto USD 1512 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Injectable Targeted Therapy Market Scope and Segmentation

Market Definition

Injectable targeted therapy is the kind of treatment that target specific or disease-causing cells without affecting the healthy cells. The targeted drug therapy has a significant advantage: it decreases the frequency of the dosages, optimizes the efficacy of the drugs and lessens the adverse effect. Injectable targeted therapy marks the cancer cells so the immune system can recognize them and destroy them.  It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Global Injectable Targeted Therapy Market Dynamics

Drivers

• Increase in Cancer Cases

The rise in cancer cases globally boosts the global cancer biological therapy market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, the majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women, causing 1.59 million deaths in 2012. This boost the market growth.

• Growth of Contraceptive Injectable

During the years, the use of injectable contraceptives has grown considerably. This increased use can mostly be attributed to their high efficacy. These contraceptives need not be taken daily; they can be administered once every month or every three months and are considered one of the safest modes of pregnancy prevention. They prevent pregnancy 99% of the time, if administered correctly. As per the Guttmacher Institute, in 2012, about 1,697,000 women used injectables for contraception in the U.S. For instance, Noristerat Injection is a reversible prescription birth control method, which is very common in the United Kingdom and other parts of Europe. This boosts the market growth.

Opportunities

• Increasing Adoption of Irregular and Unhealthy Food Consumption

The rising disposable incomes of people has pushed them to adopt a sedentary lifestyle along with irregular eating and sleeping habits. The increased consumption of food products that are rich in cholesterol, along with preserved and frozen food on a daily basis leads to the development of a huge number of acute and chronic diseases such as obesity, cancer, heart diseases, diabetes, and others.

• Development of Biologics Sector

As per the data published in The Economist, in the U.S., more than 900 biologics are under developmental process to treat more than 100 diseases. It is projected that around USD 170 billion is spent on biologics worldwide, which is anticipated to grow to almost USD 220 billion by 2017. A primary factor responsible for this trend is the increasing demand for vaccines, insulin, human growth hormone, and many modern medicines that are used to treat cancer and other chronic diseases. Biologics are primarily administered through the injectable route, thus this huge growth in the biologics market is projected to drive the injectable targeted therapy market in the coming years. This is projected to provide new hope to cancer patients.

Restraints/Challenges

• Increased Product Recalls

In recent years, several product recalls have been in the injectable targeted therapy market. Recalls can be voluntary or can result after the intercession of regulatory authorities. Any issues related to usability issues must be identified and addressed during the development process. The presence of foreign matter during the testing of retention samples in injectables lead to severe health consequences such as local inflammation, permanent impairment of a body function, phlebitis, damage and/or obstruction of blood vessels, allergic response and/or embolization in the body, and infection. Thus, all these factor associated with the product recall hamper the market growth.

• Preference for other modes of drug delivery

The injectable mode of drug delivery achieves rapid systemic levels of absorption due to its large surface area. Although, the use of injectables can lead to anxiety, needlestick injuries and infections, needle phobia, and pain. Among the other routes of drug delivery, the oral route is the most recommended one as it is cost-effective, easy to use, convenient safe, and acceptable. The topical route is preferred over injections as drugs can be applied directly to the skin, it is non-invasive, easy, and there is a high level of patient compliance.

This global injectable targeted therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global injectable targeted therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Injectable Targeted Therapy Market Scope

The global injectable targeted therapy market is segmented on the basis of type, therapy area, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Monoclonal Antibodies
• Small-Molecules
• Immunotoxins
• Others

Therapy Area

• Oncology
• Cardiometabolism
• Immunology
• Infectious Diseases
•  Neuroscience
• Ophthalmology
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Injectable Targeted Therapy Market Regional Analysis/Insights

The global injectable targeted therapy market is analysed and market size insights and trends are provided by type, therapy area, distribution channel and end-user as referenced above.

The major countries covered in the global injectable targeted therapy market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to the increasing prevalence of cancer, high demand for targeted therapies, and advanced healthcare facilities.

North America dominates the market due to the increasing awareness about the diseases and rapidly disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Injectable Targeted Therapy Market Share Analysis

The global injectable targeted therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global injectable targeted therapy market. 

Key players operating in the global injectable targeted therapy market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Endo Pharmaceuticals plc (Ireland)
• Zydus Group (India)
• Bausch Health Companies Inc. (Canada)

SKU-54219